title: Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy.
abstract: Several previous reports suggest that thrombospondin (TSP-1) may be a mediator of the antiangiogenic effects of low-dose metronomic cyclophosphamide-based chemotherapy (MC). We conducted a randomized phase II trial evaluating megestrol acetate (n = 44) versus MC (n = 44) in patients having exhausted all standard treatments. We measured the TSP-1 levels at baseline and D15. We did not observe significant differences in TSP-1 at baseline in the two arms (p = 0.07). TSP-1 levels decreased in patients receiving metronomic cyclophosphamide (from 16.6 ± 7.2 µg/ml to 12.8 ± 7.4 µg/ml; p = 0.057). The TSP-1 level was stable in patients receiving megestrol acetate. Nevertheless, the TSP-1 level driven by MC did not correlate to clinical benefit.
authors.affiliation: Centre Oscar Lambret, 3, rue F Combemale, 59020 Lille, France.
authors.forename: Amélie
authors.initials: A
authors.lastname: Lansiaux
authors.forename: Sophie
authors.initials: S
authors.lastname: Salingue
authors.forename: Amélie
authors.initials: A
authors.lastname: Dewitte
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Clisant
authors.forename: Nicolas
authors.initials: N
authors.lastname: Penel
mesh_terms: D059250:Administration, Metronomic; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005602:France; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D019700:Thrombospondin 1 / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D019700:Thrombospondin 1; D003520:Cyclophosphamide
references.citation: Cancer Chemother Pharmacol. 2006 Sep;58(3):354-60
references.pmid: 16333676
references.citation: Ann Oncol. 2002 Jan;13(1):12-5
references.pmid: 11863092
references.citation: Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22
references.pmid: 14561896
references.citation: Br J Cancer. 2010 Apr 13;102(8):1207-12
references.pmid: 20354522
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5190-8
references.pmid: 16951238